Logo

Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis

Share this

Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis

Shots:

  • The Health Canada has approved a new indication as an add-on maintenance treatment with intranasal corticosteroids in patients with CRSwNP- inadequately controlled by systemic corticosteroids or surgery
  • The approval is based on P-III studies (24wks. SINUS-24 and 52wks. SINUS-52) assessing Dupixent (300mg- q2w) + SOC intranasal corticosteroids vs PBO + intranasal corticosteroids. The studies demonstrated improvement in its 1EPs and 2EPs @24wks.
  • The approval makes the Dupixent first approved biologic in Canada for CRSwNP. Dupixent is a fully mAb inhibiting the signaling of the IL-4 and IL-13 proteins and is not an immunosuppressant

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: CHE Manager


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions